Autolus Therapeutics (NASDAQ:AUTL) Given New $10.00 Price Target at HC Wainwright

Autolus Therapeutics (NASDAQ:AUTL) had its target price increased by research analysts at HC Wainwright from $9.00 to $10.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Several other research analysts have also weighed in on AUTL. Weiss Ratings raised shares of Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 29th. Mizuho decreased their price objective on shares of Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating for the company in a report on Tuesday, March 31st. Zacks Research raised shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, March 13th. Jefferies Financial Group raised shares of Autolus Therapeutics to a “strong-buy” rating in a report on Monday, April 20th. Finally, Truist Financial raised shares of Autolus Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $8.75.

Autolus Therapeutics Trading Down 7.3%

AUTL stock traded down $0.13 during mid-day trading on Thursday, hitting $1.59. 2,561,326 shares of the company were exchanged, compared to its average volume of 1,743,251. The company has a market capitalization of $421.84 million, a PE ratio of -1.47 and a beta of 1.93. Autolus Therapeutics has a twelve month low of $1.18 and a twelve month high of $2.70. The firm has a fifty day simple moving average of $1.49 and a 200 day simple moving average of $1.51.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.02. The company had revenue of $26.22 million during the quarter, compared to analyst estimates of $26.27 million. Autolus Therapeutics had a negative net margin of 381.40% and a negative return on equity of 99.05%. As a group, sell-side analysts anticipate that Autolus Therapeutics will post -1.04 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of AUTL. Invesco Ltd. boosted its holdings in shares of Autolus Therapeutics by 53.3% in the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after buying an additional 11,381 shares during the period. Jane Street Group LLC lifted its position in Autolus Therapeutics by 809.4% in the 1st quarter. Jane Street Group LLC now owns 102,493 shares of the company’s stock valued at $159,000 after purchasing an additional 91,222 shares during the last quarter. Geode Capital Management LLC lifted its position in Autolus Therapeutics by 90.5% in the 2nd quarter. Geode Capital Management LLC now owns 164,314 shares of the company’s stock valued at $375,000 after purchasing an additional 78,058 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Autolus Therapeutics by 41.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock valued at $88,000 after purchasing an additional 11,289 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in Autolus Therapeutics by 2,891.7% in the 2nd quarter. Bank of America Corp DE now owns 975,135 shares of the company’s stock valued at $2,223,000 after purchasing an additional 942,540 shares during the last quarter. 72.83% of the stock is owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.